4D Molecular Therapeutics develops customized gene therapies using a proprietary vector platform optimized through directed evolution, targeting diseases in ophthalmology, pulmonology, and cardiology. Their products aim to provide curative treatments for conditions with significant unmet medical needs, such as reducing the treatment burden for wet age-related macular degeneration.

Acrigen Biosciences develops precision gene editing systems utilizing proprietary αCas and μCas CRISPR-Cas nucleases paired with engineered anti-CRISPR proteins to enhance the accuracy and safety of genetic therapies. The company aims to address genetic disorders by providing targeted and efficient gene editing solutions for human therapeutics.

Akadeum develops the Alerion™ Microbubble Cell Separation System, which utilizes microbubble technology for negative selection and cell depletion workflows to isolate healthier cells from biological samples. This system enhances cell viability and recovery while increasing scalability, addressing the need for more efficient and effective cell therapy manufacturing processes.

Aligned Carbon develops the Alcar wafer platform, which features semiconductor-pure, aligned carbon nanotubes grown on industry-standard wafers, enabling compatibility with CMOS fabrication processes. This technology addresses the limitations of traditional semiconductor materials by providing a 1000x improvement in power-performance, facilitating the advancement of next-generation computing systems.

Amplicore develops injectable regenerative therapeutics that repair and restore joint and spine tissues affected by osteoarthritis, cartilage damage, disc degeneration, and meniscus tears. Their proprietary minimally invasive formulations are designed for intra‑articular delivery in outpatient settings, enabling physicians to target the underlying pathology rather than just relieve pain.

Arima Genomics utilizes 3D genomics and Hi-C technology to provide detailed insights into the sequence, structure, and regulatory landscape of genomes, enabling the identification of novel biomarkers and therapeutic targets. Their solutions facilitate rapid genome assembly and analysis, addressing the need for comprehensive genomic characterization in cancer research and human health.

Avvio Medical provides an office‑based lithotripsy system that uses low‑pressure ultrasound and calcium‑targeted microbubbles to fragment kidney and ureteral stones without anesthesia or stents. The portable console integrates real‑time imaging, automated safety interlocks, and a dedicated CPT code, enabling urologists and ambulatory surgery centers to perform same‑day, cost‑effective stone removal in standard examination rooms.

Circle Pharma designs and develops bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, particularly those involved in cancer. Their computational structure-based design approach combines physics-based conformational modeling and innovative chemistry to create permeable macrocyclic peptide drug candidates.

Particella, Inc. is developing oral gene medicines using proprietary vector technology to deliver mRNA and nucleic acids directly to gastrointestinal cells. This approach targets genetic diseases and compromised mucosa, addressing the limitations of current biologics that require invasive administration methods.

Frontier Medicines utilizes a proprietary chemoproteomics platform combined with covalent chemistry and machine learning to identify and develop small-molecule therapies targeting previously undruggable disease-causing proteins. This approach enables the creation of precision medicines tailored to genetically-defined patient populations, enhancing treatment efficacy and patient outcomes.

Inhalon Biopharma is developing inhaled monoclonal antibody treatments for acute respiratory infections, including RSV and SARS-CoV-2, utilizing a novel inhalation delivery system. This approach aims to enhance treatment effectiveness and provide a convenient "test-to-treat" model for patients, facilitating timely and accessible respiratory care.

Invenio Imaging provides the NIO Laser Imaging System utilizing Stimulated Raman Histology for rapid tissue evaluation. This system delivers high-quality, unstained histology images in under three minutes directly in the operating room. The native digital images support immediate intraoperative decision-making and allow for subsequent downstream analysis of the retrieved tissue sample.

LogicInk develops electronics-free wearable sensors that provide real-time biochemical feedback on UV exposure and hydration levels, enhancing personal wellness management. By delivering actionable insights, these sensors empower users to monitor their health and make informed lifestyle choices.

Madorra develops a nonhormonal, noninvasive medical device to treat moderate to severe vulvovaginal atrophy, a condition that causes vaginal dryness in post-menopausal individuals and breast cancer survivors. By providing an alternative to pharmaceutical treatments, Madorra empowers users to manage their vaginal health effectively.

Nelumbo develops metamaterials with precise surface structures to enhance the energy efficiency and performance of heating and cooling systems, addressing the significant carbon emissions associated with traditional materials production. Their technology mitigates issues like frost and ice formation, enabling more effective and sustainable climate control solutions.

Newomics offers a Unified Multiomics Platform that utilizes swappable microflow and nanoflow modules for enhanced ionization in mass spectrometry, significantly improving sensitivity and throughput for proteomics, metabolomics, and single-cell omics applications. This technology addresses the limitations of conventional ion sources by providing a versatile, plug-and-play solution compatible with major mass spectrometer brands, enabling more efficient clinical diagnostics and biomarker discovery.

Resilient Biotics develops microbiome-based therapeutics using big data analytics and proprietary genomic databases to create precision microbial treatments for respiratory infectious diseases. Their approach aims to reduce reliance on antibiotics by utilizing healthy microorganisms to prevent pathogen colonization.

SwineTech's PigFlow platform utilizes artificial intelligence and sensor-based technologies to enhance operational efficiency in swine management by providing real-time task management and performance oversight. This system addresses labor inefficiencies and communication barriers, resulting in improved pig care and increased production metrics, such as farrowing rates and reduced mortality.

Valitor employs its proprietary Multivalent Polymer (MVP) platform to conjugate multiple copies of anti‑VEGF proteins onto a custom biopolymer scaffold, creating a long‑acting ocular biologic. The lead candidate, VLTR‑559, achieves six‑month therapeutic exposure after a single intravitreal injection while maintaining potency comparable to current short‑acting agents. The modular MVP system enables rapid development of additional ophthalmic and non‑ocular macromolecular therapeutics.

WaHa has developed the WaHa Vaporator®, a solid desiccant regeneration system that enhances energy efficiency in HVAC and Atmospheric Water Generation (AWG) applications by up to 90%. This technology addresses the urgent need for sustainable cooling solutions and reliable water sources in regions facing severe water scarcity and increasing energy demands.